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Abstract
Background: A microRNA, miR499c, has been discovered in hu-
man fetal heart which rescues mutant hearts in cardiac nonfunction 
mutant axolotl (salamander) embryos and also induces the differen-
tiation of mouse embryonic stem cells (mESCs) to form into definitive 
cardiomyocytes.
Results: Eight days after transfection with MiR499c, approximately 
75-80% of the stem cells develop typical cardiomyocyte morpholo-
gies and express the cardiac specific marker, Troponin T, as well as 
the muscle proteins, tropomyosin and α-actinin, as shown by immu-
nohistochemical staining. qRT-PCR confirms that transfection with 
MiR499c increases expression of troponin T and tropomyosin and 
further shows an increased expression of myosin as well as Wnt11 
and Sox17. Untreated controls do not show significant expression of 
these proteins.
Conclusion: It is evident that the miR499c induces the development 
of contractile myofibrils characteristic of striated cardiac muscle in-
dicating that the miR499c microRNA plays an important role in the 
differentiation of cardiomyocytes.
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Background
MicroRNAs (miRs) are an important class of small non-protein-enco-
ding RNAs that function in transcriptional and post-transcriptional re-
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gulation of gene expression including regulation of 
cardiac development, cardiomyocyte proliferation 
and differentiation. They act to control the expres-
sion of sets of genes and fundamental regulatory 
pathways and are thought of as master regulators 
of gene expression. In a recent publication, Eulalio 
et al. showed that transduction of microRNAs in 
mouse hearts increases both DNA synthesis and in-
duces cell proliferation [1]. In our recent publication 
we have reported the discovery of a novel form of 
microRNA, miR-499c, which rescues mutant hearts 
in salamander embryos [2]. The role of miR-499 in 
cardiomyocyte differentiation has been highlighted 
by several recent publications and it has been shown 
that miR-499 expression is significantly increased 
in differentiated cardiomyocytes [3]. Expression of 
miR-499 in human cardiac stem cells represses the 
miR-499 target genes, Sox6 and Rod1, enhancing 
cardiomyogenesis in vitro. Also, expression of miR-
499 is significantly increased after myocardial infarc-
tion, suggesting that expression of miR-499 may 
provide an important protective mechanism against 
heart injury [3]. Another study demonstrated that 
miR-499 promotes the differentiation of mesenchy-
mal stem cells into cardiomyocytes [4]. Thus, these 
data suggest that miR-499 plays a central role in 
cardiac development and differentiation.
Methods
RNA cloning
Random clones of 396 individual RNAs from hu-
man fetal heart were successfully acquired using the 
pDONR222 plasmid as a vector by routine procedu-
res we have described earlier [2]. DNA clones were 
synthesized by PCR using the vectors as templates 
with M13 primers and the PCR products were visua-
lized by agarose gel electrophoresis after ethidium 
bromide staining. The RNAs were synthesized by 
using an in vitro transcription reaction. RNA clones 
along with 0.1 mg/ml of lipofectamine transfection 
reagent were diluted to a concentration of 7 ng/μl 
in Opi-Mem media and transfected into the stem 
cells. 
Stem cell culture protocol
Mouse Embryonic Stem Cells (mESCs, Strain 129, 
OriCell, Cyagen Biosciences, Inc., Santa Clara, CA) 
were incubated and grown on coverslips at 37°C 
and 5% CO2, and passaged routinely according to 
our published protocols [2]. To induce differentiation, 
the mouse cells were transfected with RNA derived 
from the active clones that had been mixed with 
the transfection reagent, Lipofectamine RNAiMAX 
(Life Technologies, Grand Island, NY), diluted to a 
concentration of 50 ng/µl in OPTI-MEM medium 
(Life Technologies, Grand Island, NY) and incubated 
for 6 hours.
qRT-PCR 
Using a NucleoSpin RNAII Kit (Macherey-nagel, 
Bethlehem, PA), RNA was extracted from differen-
tiated cells treated with the active RNA and controls 
were either untreated or treated only with lipofec-
tamine. qRT-PCR was performed with a Rotor-Gene 
machine using a Rotor-Gene SYBR PCR kit (Qiagen, 
Valencia, CA) with primers designed as described in 
our earlier paper, Kochegarov et al [2]. 
Immunohistochemistry
Cells grown on coverslips were fixed in 4% parafor-
maldehyde for 30 min, rinsed in PBS with 3% BSA 
for 3 min, permeabilized in 0.1% Tween-20 and 3% 
BSA and stained overnight at 4ºC with primary an-
tibodies including: 1. monoclonal anti-tropomyosin 
CG3 antibody (Developmental Studies Hybridoma 
Bank, University of Iowa, Iowa City, IA) diluted to 
1:75; 2. anti-cardiac troponin antibodies (T 564766, 
BD Pharmingen, San Jose, CA), diluted to 1:100; 3. 
Anti- α-actinin antibodies (Developmental Studies 
Hybridoma Bank, University of Iowa, Iowa City, IA) 
diluted 1:100. The cells on the coverslips were rinsed 
with PBS containing 3% BSA for 3 min and stained 
with FITC-labelled anti-mouse antibodies ((Abcam, 
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Cambridge, MA) diluted to 1:75 for 2 hr at 4ºC. The 
coverslips with the attached cells were mounted on 
glass microscope slides with SlowFade® Gold an-
tifade reagent (Invitrogen, Grand Island, NY) and 
viewed under an Olympus Fluorview laser scanning 
confocal microscope at an excitation of 488 nm 
and emission of 520 nm for FITC. The images were 
recorded using a computerized digital camera linked 
to the microscope.
Results 
Mouse ESCs were cultured during multiple passa-
ges as undifferentiated colonies on matrigel (BD 
Biosciences, San Jose, CA) (Fig. 1A). The passaged 
stem cells were placed in small “hanging drops” 
on Petri dish lids and incubated for 48 hours. After 
48 hours, most of the stem cells had aggregated 
and formed embryoid bodies (EBs) (Fig. 1B). We 
plated these EBs on collagen-coated culture dishes 
and allowed them to attach, grow and proliferate 
for an additional 48 hours (Fig.1C). At this stage 
we treated the stem cells with RNA derived from 
the active miR-499c clone. After 8 days in culture 
most of the cells (75-80%) differentiated into cells 
with characteristic cardiomyocyte morphologies 
(Fig.1D) and these cells showed significant staining 
for tropomyosin and cardiac specific troponin T 
and α-actinin (Figs. 1E, 3B, 4). The quantity of cells 
that exhibited spontaneous cardiomyocyte diffe-
rentiation without RNA treatment was less than 
10% after 8 days in culture.
We also tested the ability of miR-499c to indu-
ce differentiation directly without the formation of 
EBs. We treated mouse embryonic stem cells daily 
for 6 hours with transfection medium containing 
the miR-499c followed by normal growth medium. 
The mouse embryonic stem cells differentiated into 
cardiomyocytes within 8 days showing changes into 
cardiomyocyte type morphologies and expressing 
cardiac troponin T in 75-80% of the cells. When 
the fluorescent staining intensity for tropomyosin 
was measured in the differentiating stem cells and 
converted into digital values by computer analysis, 
during the first seven days in culture the cellular 
tropomyosin increased progressively, strongly su-
Figure 1:  Timeline showing different stages in myocardiogenesis of mouse ESCs. A. This colony of mou-
se ESCs shows a distinct margin indicative of a relatively undifferentiated colony of ESC; B. 
Embryoid body has formed from cells in hanging drop cultures; C. Spreading and proliferation 
of cells on gelatin coated tissue culture plates; D. Phase contrast image of mouse ESCs treated 
with cardiogenic microRNA-499c. A majority of the cells have taken on shapes characteristic 
of early stage myocardiocytes; E.  Differentiated cells after 8 days of treatment with the car-
diogenic inducing microRNA-499c stained with antibody against tropomyosin. The cells show 
significant accumulations of tropomyosin suggesting a myocardial phenotype..
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ggesting that the differentiation of the stem cells 
into cardiomycytes was taking place (Fig. 2).
Also after 7 days of treatment with mir499c, the 
stem-cells acquired characteristic cardiomyocyte 
morphologies (Fig. 3A) and showed tropomyosin 
(Figs. 3B, 4B), troponin T (Fig. 4A) and α-actinin 
(Fig. 4C) incorporated into myofibrils indicative of 
definitive cardiomyocytes (Figs. 3B, 4). In untreated 
controls, most of the stem cells became fibroblast-
like in appearance without significant tropomyosin 
or troponin expression (Figs. 3C, 3D). High resolu-
tion confocal imaging revealed myofibril organiza-
tion after immunofluorecent staining for the car-
diac specific troponin T, tropomyosin and α-actinin 
Figure 2:  Time course of stem cell-derived cardiomyocyte differentiation revealed by immunofluores-
cent staining with antibodies for tropomyosin after treatment with microRNA-499c. The 
fluorescently labeled cells are scanned for brightness and intensity and quantitated by com-
puter digitization. The data show a gradual increase of the tropomyosin expression up 
to 7 days. Numbers on the bottom of the graph indicate day(s) after the microRNA-499 
transfection of the stem cells. Numbers on the side represent the relative intensities of the 
fluorescent staining in the microscope fields with the brightest field (7 days) being assigned 
a value of 100.
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in mESC-derived cardiomyocytes treated with miR-
499 (Fig. 4).
In our quantitative PCR studies, we examined the 
expression of various species of growth factors, Wnt, 
Sox and BmP, as well as the contractile proteins, tro-
ponin T, tropomyosin and myosin, with and without 
miR-499c treatment. We found that expression of 
Wnt11 and Sox17 increased significantly in response 
to the miR-499c treatment (Fig. 5). Expression of 
other types of Wnt and Sox did not change signifi-
cantly (not shown). Also with the expression of Wnt, 
cardiac marker contractile proteins including cardiac 
troponin T, tropomyosin and myosin increased signi-
ficantly in 4 days and were at even higher levels after 
8 days of the miR-499 treatment, corroborating the 
observations made using immunofluoresent confo-
Figure 3:  Mouse ESCs differentiated into spindle-shaped cardiomyocytes 8 days after transfection with 
microRNA-499 (A, B); mouse ESC 8-day parallel controls, without transfection (C, D).  A.  Many 
of the microRNA-499c-treated stem cells show characteristic cardiomyocyte shapes;  B. The 
treated cells stain intensely for tropomyosin with anti-tropomyosin antibodies;  C. Untreated 
cells have shapes that are more typical of fibroblasts and other non-cardiac connective tissue 
cells;  D. Very little staining is observed with anti-tropomyosin antibodies in these untreated 
control stem cells.
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cal microscopy. Without miR-499c treatment, the 
Wnt11, Sox17, troponin T, tropomyosin and myosin 
did not increase significantly, but remained approxi-
mately at 0 day (base) levels (Fig. 5).
Discussion 
In recent studies we have identified a new precur-
sor of a microRNA which we have called miR-499c 
[2]. This novel miR-499c sequence partially overlaps 
with both miR-499a and miR-499b and contains an 
additional short 22 base pair (bp) sequence. In our 
previous publication, we showed that this microR-
NA promotes myofibrillogenesis and rescues mutant 
axolotl hearts by promoting the differentiation of 
non-muscle cells in the mutant myocardium into 
contracting cardiac muscle cells [2]. This fetal hu-
man heart microRNA appears to rescue the mutant 
axolotl hearts in a manner indistinguishable from 
our originally discovered axolotl myofibril inducing 
RNA (MIR) [5]. We hypothesize that these two RNAs 
promote myofibrillogenesis and rescue the mutant 
salamander hearts by binding and interacting with 
a common protein binding complex. They also in-
duce differentiation of mouse embryonic stem cells. 
Spontaneous cardiomyocyte differentiation of mou-
se stem cells was described previously by Mummery 
et al. [6]. In that study, stem cells formed embryoid 
bodies (EBs) which then attached, proliferated and 
differentiated spontaneously. We found that spon-
taneous cardiomyocyte differentiation without RNA 
treatment was less than 10% and a large majority 
of these cells showed fibroblast-like shapes. Trans-
fection of mouse ESCs with miR-499c significantly 
increased the formation of differentiated cardiomyo-
cytes to 75-80% as revealed by immunohistochemi-
cal staining for cardiac specific troponin T, tropom-
yosin and α-actinin and by directing the cell mor-
phologies into typical cardiomyocyte forms (Fig. 4).
We also tested the ability of miR-499c to in-
duce stem cell differentiation directly without the 
formation of EBs. We treated mouse embryonic 
stem cells daily for 6 hours with transfection me-
dium containing miR499c. In this experiment, stem 
cells differentiated into definitive cardiomyocytes in 
8 days as revealed by positive immunofluorescent 
staining for cardiac troponin T and tropomyosin and 
by showing typical myocardial cell morphologies. 
Figure 4:  Fluorescent imaging of stem cell-derived cardiomyocytes treated with miR-499c after 8 days in 
culture stained with antibodies against: A. cardiac troponin T; B. tropomyosin; and C. α-actinin.  
The miR-499c treated cells reveal significant staining for the muscle proteins showing they 
have differentiated into cardiomyocytes. Stem cells that are untreated, treated with lipofectin 
only or treated with RNA derived from a non-active clone show very little staining for these 
contractile cardiac muscle proteins.
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Figure 5:  miR-499 induced expression of proteins in mouse ESCs at 0, 4 and 8 days. All of the proteins/
factors: Wnt11, Sox17, troponin T, tropomyosin and myosin show moderate increases after 4 
days and more dramatic increases at 8 days in culture.  In the control stem cells without miR-
499 treatment, even at 8 days in culture the proteins/factors remain essentially at the base 
levels recorded at 0 days.
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Interestingly, during normal in vivo embryonic heart 
development in mouse, the first cardiac muscle tis-
sue also appears on the 8th day of development. 
Thus, our data have clearly and unequivocally de-
monstrated the ability of our newly-discovered miR-
499c to rescue mutant hearts in axolotl embryos by 
forming cardiomyocytes from nonmuscle cells and 
by inducing the differentiation of mouse embryonic 
stem cells to form into cardiomyocytes. Our findings 
are supported further by recent publications which 
show that miR-499 induces the differentiation of 
mesenchymal stem cells into cardiomyocytes [4]. In 
another research study, miR-499 transduction into 
human embryonic stem cells significantly increased 
the yield of human embryonic ventricular cardiom-
yocytes (from 48% to 72%) along with increased 
contractile protein expression [7]. Further, it has 
been shown that miR-499 expression is significantly 
increased in differentiated cardiomyocytes [3]. 
Also, in our present study, expression of Sox6 did 
not show a statistically significant change with miR-
499c treatment, while expression of Sox11, which 
activates the non-canonical Wnt pathway, was sig-
nificantly increased after 4 or 8 days. In addition, 
we found that Wnt11 expression correlated with an 
increase in expression of transcription factor Sox17. 
The research we report here, to our knowledge, is 
the first definitive evidence implicating Wnt11 as 
an important signal in cardiac differentiation. We 
hypothesize that Wnt11 may activate expression of 
the transcription factor, Sox17, which then initiates 
cardiac differentiation. Therefore, on the basis of 
our current results, one possible explanation is that 
in undifferentiated stem cells, transcription factors 
Oct 3/4 and Sox2 are expressed constitutively and 
bind to DNA to keep cells in a pluripotent condi-
tion, while in differentiating cells, Wnt11 activates 
expression of Sox17 and this in turn directs the cells 
to form into cardiomyocytes.
Of the many individuals worldwide who su-
ffer heart attacks each year, there are a number 
of treatments that currently are used to reduce 
their symptoms and help in the recovery process. 
Although these interventions improve the quality 
of life for some, many do not fully recover because 
connective scar tissue replaces the cardiac muscle 
in the infarcted area and the heart loses its efficien-
cy in pumping the blood. The research we report 
here may lead to better treatments for patients in 
the future who suffer from myocardial infarctions or 
other heart diseases that negatively affect myocar-
dial tissue. It is possible that the use of MiR-499c, 
in combination with induced pluripotent stem cells 
derived from that same patient, could be used to 
repair the damaged cardiac muscle tissue, leading 
to a much better prognosis for heart-attack victims 
in the future.
Conclusion
We have found that MiR-499c promotes the di-
fferentiation of mouse ESCs into cardiomyocytes 
as well as rescues the development of mutant 
embryonic hearts in the salamander, Ambystoma 
mexicanum. MiR-499c appears to be an important 
regulator of vertebrate heart embryonic develop-
ment and cardiomyocyte differentiation. This may 
take place by Wnt11 activating the expression of 
Sox17 which then directs the cells to differentiate 
into cardiomyocytes. Our findings may have impor-
tant future clinical implications for the treatment of 
human heart damaged from myocardial infarction 
or other disease processes by replacing the dama-
ged tissue with stem cells derived from the patient 
and induced to form into new myocardial cells using 
the active microRNA, miR-499c. The hope would 
be that such patients, with their hearts repaired by 
newly-formed myocardial cells, could return to a 
normal lifestyle again. 
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